SIN MASTER F
0 (0 Likes / 0 Dislikes)
It was the first few hours of SIN
and a doctor came in
to my immense joy,
telling us that yesterday
she conducted the first therapy
with Emgality for an initial patient
who was quite happy.
The pen was super easy to use
and there was a patient that finally
could gain access to Emgality.
Hello everyone from Bologna and welcome to SIN.
We are here with our Emgality.
One of the activities we have
at the stand is virtual reality
the goal of which is to demonstrate the mechanism of action
which as we know
towards the ligand and not the receptor.
And we've tried to communicate this
in a very engaging way
as they must launch Galcanezumab toward the CGRP.
The feedback we've received has been very positive.
It's been a great experience,
giving you a good idea of what can
happen at the cellular level.
An exciting experience.
Yes, it's been a useful experience
also because of the fact that memory
is primarily visual, so
evidently these images
are maybe even more useful than a classroom lesson.
You can touch with your own hand what
the action is for a drug of this type.
An instructive and interesting experience.
"After the virtual reality, we give the doctors
the opportunity to learn more about the data from Emgality
in a fun and engaging way using the touchscreens
so they have the opportunity
to select the data that they think
is applicable and compare it to the original.
In this way, they learn about the safety,
efficacy and tollerability of our data.
We really hope you enjoy the SIN congress
and don’t miss out the opportunity to come to our booth."
Medical is also present at SIN.
We are very happy to have returned to the
field of neuroscience
and so everything is going quite well
and we look forward to the highlights for tomorrow and the day after.